Dr. Hazuda's research on the HIV-1 integrase enzyme catalyzed the identification of viral integration inhibitors, the validation of this mechanism in vivo, and the understanding of mechanisms of resistance. These accomplishments resulted in the development and approval of raltegravir (tradename ISENTRESS), the first integrase inhibitor licensed for treatment of HIV-1 infection.